Astellas Pharma Gmbh

Mitsubishi Electric Corporation

Takehiro Miyazaki

Wataru Hamaguchi

Isao Kinoyama

Yohei Koganemaru

Takuya Washio

Ryuichi Sekioka

Osamu Kaneko

Disclosed is a vehicle data abnormality determination device including a storage unit for pre-storing a 2-byte remainder term which is a result of a CRC arithmetic operation on a target area for arithmetic operations in a predetermined memory area, and an arithmetic operation unit for performing a CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation. Because when performing the CRC arithmetic operation, the vehicle data abnormality determination device performs the CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation after performing an arithmetic operation on the target area, the vehicle data abnormality determination device always makes the computed result be zero when the data has not been falsified, and can detect whether or not the data has been falsified easily and properly.

Vehicle data abnormality determination device

To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HTreceptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HTreceptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.

Tetrahydroisoquinoline derivative

[Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HTreceptor modulating action, is provided. [Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z, Z, Z, Zand Zis nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HTreceptor modulating actions and excellent pharmacological actions based on the 5-HTreceptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed. 

Nitrogenous-ring acylguanidine derivative

Growing community of inventors

Tokyo, Japan

Takehiro Miyazaki